YOLFTbeta
Connect Biopharma Holdings Ltd

Connect Biopharma Holdings Ltd

CNTB · NASDAQ · Healthcare / Biotechnology

0.6772USD+0.01 (+1.79%)

Price History

Full chart

Market Stats

Previous Close0.6653
Open0.6825
Day Range0.641 – 0.6999
52-Week Range1.06 – 3.82
Volume233.68K
Market Cap69.27M
P/E (TTM)0.00
Forward P/E0.77
EPS-1.23
Dividend Yield0.00%
Beta-0.18
50-Day Avg2.05
200-Day Avg2.39

About

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Barry David Quart Pharm.D.
  • Employees64
  • Headquarters3580 Carmel Mountain Road, San Diego, CA, United States, 92130, USA
  • Websitehttps://www.connectbiopharm.com

Leadership

  • Dr. Barry David Quart Pharm.D.CEO & Director · b. 1957
  • Mr. David L. Szekeres J.D.President · b. 1974
  • Ms. Lisa Peraza CPASenior Vice President of Finance · b. 1977
  • Mr. Jeff Cohn J.D.General Counsel & Corporate Secretary · b. 1982
  • Mr. Sean T. RistineVice President of Human Resources · b. 1970
  • Dr. Lei Sun Ph.D.VP of Biologics & Head of CMC · b. 1964
  • Dr. Srikanth Pendyala M.D.Senior Vice President of Clinical Development(Consultant)
  • Ms. Kimberly J. ManhardExecutive VP & Chief Development Officer · b. 1960

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-0000026.03M64.00K
Growth (%)--------99.75%
Cost of Revenue----1.03M988.00K660.00K-
Gross Profit-----1.03M-988.00K26.03M64.00K
Gross Margin------100.00%100.00%
Operating Expense----118.29M68.07M48.48M58.14M
Operating Income--15.99M-30.30M-98.11M-119.32M-69.06M-22.45M-58.07M
Operating Margin-------86.24%-90740.63%
EBITDA--24.78M-118.21M-201.36M-116.74M-61.27M-14.74M-54.58M
EBITDA Margin-------56.64%-85279.69%
Net Income--24.46M-119.37M-202.27M-118.09M-62.11M-15.63M-55.48M
Net Income Margin-------60.03%-86687.50%
R&D-15.44M23.12M80.50M96.63M53.00M29.26M37.80M
R&D as % of Total Revenue------112.38%59059.38%
Interest Expense07.69K6.43K6.91K21.03K23.00K--

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets69.29M7.73M25.44M291.05M174.01M127.38M101.28M56.08M
Total Liabilities88.70M13.91M49.47M18.80M16.52M25.88M9.12M14.10M
Total Equity-19.41M-6.18M-24.03M272.26M157.49M101.50M92.17M41.98M
Cash61.34M6.41M23.68M267.72M79.01M105.66M78.23M38.34M
Total Debt87.73M18.29K21.41K125.00K431.00K465.00K178.00K690.00K
Net Debt26.39M-6.39M-23.66M-267.59M-78.58M-105.20M-78.05M-37.66M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-69.03M-13.09M-25.61M-544.93M-99.27M-47.93M-23.61M-51.21M
Investing Cash Flow58.08M-484.70K449.15K-34.02M-83.44M75.16M-3.45M9.82M
Financing Cash Flow368.95M-57.45K140.74M1.32B-91.29K-246.00K227.00K1.09M
Capital Expenditure1.19M155.52K2.34M47.53M4.28M294.00K750.00K434.00K
Free Cash Flow--13.25M-27.95M-592.46M-103.55M-48.22M-24.36M-51.64M
Dividends Paid---243.00K----
FCF to OCF-101.19%109.16%108.72%104.31%100.61%103.18%100.85%
Dividend Paid to FCF----0.04%----

Earnings

Report DateMar 31, 2022Sep 12, 2022Sep 12, 2023Mar 31, 2025May 15, 2025Aug 13, 2025Nov 12, 2025Mar 31, 2026Apr 1, 2026Aug 12, 2026Nov 11, 2026
EPS Estimate-0.52-0.21-6.920.00-0.26-0.22-0.23-0.30-0.28-0.32-0.27
EPS Actual-0.50-0.90-0.54-0.42-0.19-0.23-0.31-0.27-0.27-0.27-
Surprise3.85%-328.57%92.20%-26.92%-4.55%-34.78%10.00%4.60%15.63%-
TimingAfter-hoursAfter-hoursAfter-hours-Pre-marketPre-marketPre-marketAfter-hours-After-hours-

Key Statistics & Ratios

Market Cap69.27M
Enterprise Value36.18M
Trailing P/E0.00
Forward P/E0.77
Price / Sales23.46
Price / Book2.50
EPS-1.23
Book Value0.427
Revenue (TTM)2.95M
Gross Profit (TTM)2.95M
EBITDA-69.73M
Profit Margin0.00%
Operating Margin-635.98%
Return on Equity-140.51%
Return on Assets-69.75%
Shares Outstanding62.97M
Shares Float21.07M
Beta-0.18
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 6.50
  • Strong Buy
    1
  • Buy
    1

Ownership Breakdown

Institutions
56.13%
Insiders
29.68%
Retail / Other
14.19%

Top Institutional Holders

  • Quadrature Capital Limited
    42.30K0.07%
  • EverSource Wealth Advisors, LLC
    00.00%

Top Fund Holders

  • T. Rowe Price Small-Cap Index I
    2.28K0.00%